2022-09-21| In-DepthSpecial

ESMO 2022: Promising Trials Highlights That Are Worth Following

by Elena Chen
Share To
This year's event, organized by the European Society for Medical Oncology (ESMO), took place in Paris from September 9 to 13. This congress is an oncology event for international HCPs, the majority from Europe. 

As the opening conference remarked, sustainability will be the heart of many discussions. “Sustainability is about maintaining important, high-quality processes over time. In oncology, seeing the rise in cancer cases, we need to ask ourselves how we can ensure the essential process of caring for patients can be maintained,” said ESMO President Prof. Solange Peters.

For cancers that are not currently avoidable, screening and early detection can both maximize individuals’ chances of survival and alleviate the burden on health systems by reducing the proportion of patients with advanced diseases who require costly, chronic therapies and care.  

This year has been a fructiferous year for oncologists, with many positive clinical trial results and upgrades from previous clinical trials. As many new drugs are ongoing, we’ll focus on those discussed most lately. 

It's free! Log in now to read

Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
Scroll to Top